Navigation Links
Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
Date:5/30/2008

Woodcliff Lake, N.J., May 15, 2008The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy, said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine.

About Study 211 Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients received a median of four cycles of eribulin mesylate (range 1-27). No premedication to prevent hypersensitivity was required.

Two-hundred sixty-nine patients met the key inclusion criteria. In patients who received a median of four cycles of eribulin mesylate, Overall Response Rate (ORR) by Independent Review (IR) was 9.3% (all Partial Responses (PR); 95% confidence interval [CI]: 6.1%-13.4%). Investigator-assessed ORR was 14.1% (1 CR; 95% CI: 10.2%-18.9%). Nearly half (46.5%) the patients had stable disease (SD) after treatment with eribulin mesylate. The clinical benefit rate (CBR, defined as CR+PR+SD 6 months) was 17.1% (95% CI: 12.8%-22.1%).

The median duration of response was 4.2 months (126 days, range: 42 -258 days; 95% CI: 86-147). Median progression-free survival (PFS) was 2.6 months (79 days, range: 1*-397 days), and the median overall survival (OS) rate was 10.3 months (315 days, range: 19-604 days; 95% CI: 279-350). The six-month PFS and OS rates were 16.0% (95% CI: 8.6-17.0) and 72.3%, respectively (95% CI: 66.9-77.6).

The safety analysis included all 291 patients who received treatment with eribulin mesylate. Patients with up to Grade 2 peripheral neuropathy were included in the study. The most frequently reported Grade 3 (severe) or Grade 4 (disabling or life- threatening) adverse events were neutropenia (a decrease in the number of granular white blood cells, 54%); febrile neutropenia, 5.5%, leukopenia (low white blood cell count, 14%), and weakness/fatigue (10%; no Grade 4 events). Grade 3 peripheral neuropathy (a functional disturbance or damage to nerves outside the brain and spinal cord) was reported in 5.5% of patients. No Grade 4 peripheral neuropathy events were reported. No correlation was seen between Grade 2 peripheral neuropathy and deterioration.

"In this study, eribulin mesylate appeared to have an acceptable tolerability profile, particularly with regard to the low incidence of peripheral neuropathy," noted Vahdat. "None of the reported cases of neuropathy were disabling, suggesting that eribulin mesylate, if approved, may be a useful addition to the treatment armamentarium for advanced breast cancer."


'/>"/>

Contact: Judee Shuler
201-746-2241
Eisai Inc.
Source:Eurekalert

Related biology news :

1. UM coral scientist Peter Glynn wins award for scholarly activity
2. Blood pressure drug telmisartan shows powerful activity against stroke
3. Cold Spring Harbor Protocols highlights a method that captures cell growth and activity
4. CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
5. Cell-based therapy shows promise in patients with Parkinsons disease
6. Scientists test device to track medication adherence in patients with HIV/AIDS
7. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
8. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
9. Pregnant patients lose out in breast cancer treatment; a new approach is needed
10. Mental stress reduces blood flow to the heart in patients with gene variation
11. 2 new therapies show promise for cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016   Avanade is ... Formula One teams in history, exploit biometric data in ... performance and maintain the competitive edge against their rivals ... Avanade has worked with Williams during ... of biometric data (heart rate, breathing rate, temperature and ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , ... today it has seen a third consecutive year of ... sensor technology in 2016 with a 360 percent increase ... year. This increase was driven by sales of its ... robust interest in its technology for hearables for fitness ...
(Date:12/2/2016)... PUNE, India , December 1, 2016 /PRNewswire/ ... Market by Authentication type (Fingerprint, Voice), Future Technology (Iris ... Vehicle), and Region - Global Forecast to 2021", ... be USD 442.7 Million in 2016, and is ... 2021, at a CAGR of 14.06%. ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... PRINCETON, N.J. , Dec. 8, 2016 /PRNewswire/ ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today the ... trial with SGX942 (dusquetide), a first-in-class Innate Defense ... (OM) in head and neck cancer patients undergoing ...
(Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. ... a Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based ... “The System Integrator Partner certification gives customers confidence that our engineers are fully ...
Breaking Biology Technology: